printemailclick to share buttonfacebooktwitterlinkedin
Ontario Steering Committee for Cancer Drugs (OSCCD)
 

The Ontario Steering Committee for Cancer Drugs (OSCCD) was created in 2013 to enhance and support the administration of Ontario's cancer drug programs. The committee advises the Ministry of Health and Long-Term Care's Ontario Public Drug Programs and Cancer Care Ontario's Provincial Drug Reimbursement Programs.

Committee Objective

The objective is to provide evidence-based clinical, health research and health economic guidance to the Executive Officer (EO) of Ontario Public Drug Programs (OPDP) on: provincial cancer drug funding policies and decisions, program evaluation and drug-specific studies, and enhancements to cancer drug programs or initiatives in Ontario. For more information on cancer drug funding and decision making in Ontario, please see the Public Drug Funding and Administration page or visit one of these sites:

OSCCD Cancer Drug Reviews

The OSCCD reviews select cancer drugs for public funding in Ontario. Review summaries are available here.

Membership

The OSCCD is comprised of members with expertise from different disciplines including medical oncology, hematology, pharmacy and health economics. It also has patient representation.

All OSCCD members are selected by the Executive Officer of Ontario Public Drug Programs (OPDP), in consultation with Cancer Care Ontario (CCO).

Terms of Reference

Dr. Craig Earle (Chair)
Director, Health Services Research Program
Cancer Care Ontario and the Ontario Institute for Cancer  Research
Senior Scientist, Institute for Clinical Evaluative Sciences
Medical Oncologist, Sunnybrook Odette Cancer Centre

Dr. Kelvin Chan
Medical Oncologist, Sunnybrook Odette Cancer Centre                                                                  
Assistant Professor, Department of Medicine, University of Toronto

Dr. Parneet Cheema
Medical Oncologist, Sunnybrook Odette Cancer Centre

Dr. Matthew Cheung
Assistant Professor, Department of Medicine, University of Toronto
Clinician-Investigator/Clinical Hematologist, Sunnybrook Health Sciences Centre

Dr. Peter Ellis
Associate Professor, Department of Oncology, McMaster University
Medical Oncologist, Juravinski Cancer Centre

Dr. Katherine Enright
Medical Oncologist Trillium Health Partners, Credit Valley

Dr. Christopher Longo
Associate Professor, Health Policy and Management, DeGroote School of Business
Director, Health Services Management (MBA), DeGroote School of Business

Joanne MacPhail
Public Member
Co-Chair, Patient and Family Advisory Council, Cancer Care Ontario

Dr. Amit Oza
Professional Medicine, University of Toronto
Co-Director, Bras Drug Development Program
Director, Cancer Clinical Research Unit, Princess Margaret Cancer Centre

Dr. Zahava Rosenberg-Yunger
Adjunct Professor, Research Associate, Ryerson University

Dr. Srikala Sridhar
Medical Oncologist, Division of Medical Oncology, Princess Margaret Hospital          
Assistant Professor, Department of Medicine, University of Toronto  

Laura Wilcock
Oncology Pharmacist, Lakeridge Health, Durham Regional Cancer Centre

Meeting Dates and Agenda

Click on the link to view the agenda.

Meeting Date / Agenda
Monday, November 25, 2013
Wednesday, December 12, 2013
Thursday, February 27, 2014
Tuesday, April 28, 2014
Tuesday, June 26, 2014
Tuesday, September 8, 2014
Tuesday, October 27, 2014
Tuesday, December 11, 2014
* Meeting dates and agendas subject to change. Agendas posted as available.
Last modified: Wed, Sep 30, 2015
cancer care ontario | action cancer ontario   620 University Avenue Toronto Ontario, Canada M5G 2L7   Phone: 416.971.9800 Fax: 416.971.6888

Please help improve the quality of our website by answering 10 brief questions in our online survey. Would you like to participate?

YesNo